| | |  | | | | Record from Web of Science® | | | | | | |
| Identification of a heparin-binding hemagglutinin present in mycobacteria |
|
|
| Author(s): Menozzi FD, Rouse JH, Alavi M, LaudeSharp M, Muller J, Bischoff R, Brennan MJ, Locht C |
| Source: JOURNAL OF EXPERIMENTAL MEDICINE Volume: 184 Issue: 3 Pages: 993-1001 Published: SEP 1 1996 |
| Times Cited: 102 References: 47 |
| Abstract: Adherence to mammalian host tissues is an important virulence trait in microbial pathogenesis, yet little is known about the adherence mechanisms of mycobacteria. Here, we show that binding of mycobacteria to epithelial cells but not to macrophages can be specifically inhibited by sulfated carbohydrates. Using heparin-Sepharose chromatography, a 28-kD heparin-binding protein was purified from culture supernatants and cell extracts of Mycobacterium bovis and Mycobacterium tuberculosis. This protein, designated heparin-binding hemagglutinin (HBHA), promotes the agglutination of rabbit erythrocytes, which is specifically inhibited by sulfated carbohydrates. HBHA also induces mycobacterial aggregation, suggesting that it can mediate bacteria-bacteria interactions as well. Hemagglutination, mycobacterial aggregation, as well as attachment to epithelial cells are specifically inhibited in the presence of anti-HBHA antibodies. Immunoelectron microscopy using anti-HBHA monoclonal antibodies revealed that the protein is surface exposed, consistent with a role in adherence. Immunoblot analyses using antigen-specific antibodies indicated that HBHA is different from the fibronectin-binding proteins of the antigen 85 complex and p55, and comparison of the NH2-terminal amino acid sequence of purified HBHA with the protein sequence data bases did not reveal any significant similarity with other known proteins. Sera from tuberculosis patients but not from healthy individuals were found to recognize HBHA, indicating its immunogenicity in humans during mycobacterial infections. Identification of putative mycobacterial adhesins, such as the one described in this report, may provide the basis for the development of new therapeutic and prophylactic strategies against mycobacterial diseases. |
| Document Type: Article |
| Language: English |
Addresses:
1. US FDA, CBER, LAB MYCOBACTERIA, ROCKVILLE, MD 20852 USA
2. INST PASTEUR, LAB MICROBIOL GENET & MOL, INST NATL SANTE & RECH MED, U447, F-59019 LILLE, FRANCE
3. TRANSGENE SA, F-67082 STRASBOURG, FRANCE |
| Publisher: ROCKEFELLER UNIV PRESS, 222 E 70TH STREET, NEW YORK, NY 10021 |
| Subject Category: Immunology; Medicine, Research & Experimental |
| IDS Number: VG868 |
| ISSN: 0022-1007 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |